CalciMedica, Inc. (CALC) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-12

Key Insights

CalciMedica disclosed Q1 2026 financial results via press release on May 12, 2026, indicating the company is actively reporting operational performance to shareholders as required.
The filing shows A. Rachel Leheny, Ph.D. serving as Chief Executive Officer, confirming stable executive leadership at the time of this quarterly earnings announcement.
The company trades on The Nasdaq Capital Market under ticker CALC with registered common stock, maintaining its public company status and market access for capital raising.
The 8-K is a standard quarterly earnings disclosure without indication of material agreements, leadership changes, or significant corporate events that would require Item 5.02, 1.01, or other material event disclosures.

Want the newest filings?

This analysis covers the filing from 2026-05-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-18

CalciMedica, Inc. has received two notices from Nasdaq indicating non-compliance with listing requirements related to minimum market value of listed securities ($35 million) and minimum bid price ($1 per share).
The company has 180 days to regain compliance with these requirements, which could include conducting a reverse stock split or taking other actions.
Failure to regain compliance within the allotted time could result in the company's stock being delisted from the Nasdaq Capital Market.

Filed: 2026-03-03

CalciMedica, Inc. reported its financial results for the full year 2025, showing a slight decline in revenue compared to the previous year.
The company did not provide any forward-looking guidance in its earnings release, which could indicate uncertainty about its future prospects.
There were no notable leadership changes or material agreements announced in this 8-K filing.

Filed: 2026-01-28

CalciMedica, Inc. has discontinued its Phase 2 KOURAGE clinical trial evaluating Auxora in patients with acute kidney injury and acute hypoxemic respiratory failure, following a recommendation from the Independent Data Monitoring Committee.
The decision to discontinue the trial was due to a safety concern identified during the interim data review, though there were no deaths related to the study drug.
The company plans to perform a comprehensive review of the unblinded clinical data to assess the impact of baseline characteristics, disease severity, and other factors on patient outcomes, which could inform future clinical evaluation of Auxora.

Filed: 2026-01-28

CalciMedica has discontinued its Phase 2 KOURAGE clinical trial based on a recommendation from the Independent Data Monitoring Committee, indicating potential issues with the trial or product candidate.
The company has updated its financial guidance, with its existing cash, cash equivalents, and short-term investments now expected to fund operations into the fourth quarter of 2026, earlier than the previously disclosed second half of 2026.
The discontinuation of the KOURAGE trial and resulting reduction in planned operating expenses could have a significant impact on the company's financial position and future development plans.

Other reports for CalciMedica, Inc.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.